Dr. Scott Michael Gilbert, MD

Dr. Gilbert practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Gilbert's NPI, 1437240983, was assigned on September 28, 2006. Dr. Gilbert graduated from Vagelos College of Physicians and Surgeons in 2000. Dr. Gilbert holds Florida license ME102228.

Dr. Gilbert's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Gilbert's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Gilbert is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Gilbert to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gilbert practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Gilbert's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Gilbert is board certified in urology by the American Board of Urology. Dmand AI has Dr. Gilbert's licenses on file in 3 states: Florida, Michigan and New York.

Dmand AI lists bladder removal, enlarged prostate transurethral surgery (TURP), kidney removal surgery, kidney stones, prostate cancer, urinary endoscopy, urine flow blockage and UTI among the conditions Dr. Gilbert treats.

CMS data shows 567 Medicare services from Dr. Gilbert across 13 procedure codes in 2024, for 302 Medicare patients. Medicare paid $72,726 for them.

CMS counts 302 Medicare patients who saw Dr. Gilbert in 2024. The largest group is 75 to 84, with 141 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gilbert's median patient age at 74, with 24% women.

In 2024, Dr. Gilbert wrote 231 Medicare Part D claims for 119 patients. 97% of them were for generic drugs. CMS names the drug for 187 of them, across 4 drugs with 11 or more claims each, at $1,334 in total drug cost. In 2023, CMS named 147 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Gilbert for performance year 2024, reported as part of a group. Dr. Gilbert accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gilbert as offering telehealth. CMS counts 11 procedures of prostate resection by Dr. Gilbert, more than 60% of the clinicians it reports for that procedure.

Dmand AI links 147 papers to Dr. Gilbert, published from 2007 to 2024. 2019 was the busiest year, with 9. The most frequent topics are Urinary Bladder Neoplasms, Cystectomy and Prostatic Neoplasms. Dr. Gilbert has published most often in J Urol. Dr. Gilbert's most frequent co-authors are Wade J. Sexton, MD, Philippe E. Spiess, MD and Michael A. Poch, MD.

Dmand AI links Dr. Gilbert to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Urinary Bladder Neoplasms and Urinary Bladder Diseases. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 2.

CMS Open Payments shows 7 general payments to Dr. Gilbert from 4 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Haemonetics Corporation paid the most, $136.

Dmand AI lists 13 awards for Dr. Gilbert, most recently CMS Stage 1 EHR in 2013.

Dr. Gilbert graduated from Vagelos College of Physicians and Surgeons in 2000. Dr. Gilbert is a member of ACS, ASCO, AUA and Society of Urologic Oncology.

Dr. Gilbert is in network with 7 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.